Precision medicine isn’t so precise. Thousands of patients with advanced cancer across the country (and world) get next-generation sequencing to identify actionable mutations. Many of them then receive targeted therapies for indications that haven’t been well characterized in clinical trials. We’re left never knowing how effective or toxic these “precision” approaches are in the real world. In the Netherlands, the Drug Rediscovery Program (DRUP) harnesses that process to prospectively collect efficacy data on off-label targeted therapy use. As a result, successful off-label therapies can be identified more quickly and communicated to patients and physicians. | van der Velden, Nature 2019


Popular Posts